Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
i-charging Receives Frost & Sullivan’s 2025 European Competitive Strategy Leadership Award for Excellence in EV Ultra-fast and Megawatt Charging
Recognized for delivering strategic innovation, advanced technology, and customer-focused solutions that redefine EV…
